April 27, 2018 / 11:35 AM / 3 months ago

Gilead's three-drug HIV regimen wins European panel approval

April 27 (Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

The Committee for Medicinal Products for Human Use (CHMP) backed the treatment, Biktarvy, a once-daily tablet that combines two previously approved drugs - emtricitabine, tenofovir alafenamide and a new integrase inhibitor bictegravir.

The CHMP opinion sets the stage for a likely approval by the European Commission.

The combination, which was approved by the U.S. Food and Drug Administration in February, faced critisism from rival ViiV Healthcare, a joint venture majority-owned by GlaxoSmithKline Plc with Pfizer Inc and Shionogi Ltd.

The joint venture filed a lawsuit soon after the U.S. regulator's approval alleging that Gilead was infringing patents on ViiV's dolutegravir, a component of the company's triple-drug HIV treatment Triumeq. (Reporting By Justin George Varghese in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below